Cardiologs Holter Platform vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cardiologs Holter Platform

by Philips (Cardiologs)

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Tool A, the Cardiologs Holter Platform, is an AI-powered solution for the fast and accurate diagnostic analysis of existing Holter ECGs, detecting over 20 types of arrhythmias. Conversely, Tool B, Tempus ECG-AF, is an AI-based algorithm focused on predicting the risk of new-onset atrial fibrillation/flutter within 12 months for patients aged 65 or older using 12-lead ECGs. While both utilize AI for cardiac rhythm analysis, Tool A is a broad diagnostic tool for current conditions, whereas Tool B is a predictive risk assessment tool for a specific future condition in a defined demographic.

Choose Cardiologs Holter Platform if…

Choose the Cardiologs Holter Platform if your practice requires a highly efficient, AI-powered solution for comprehensive and rapid analysis of Holter ECGs. This tool is ideal for cardiologists seeking to quickly and accurately diagnose a broad spectrum of over 20 arrhythmias, streamlining their diagnostic workflow and integrating seamlessly with existing EMR systems.

View Cardiologs Holter Platform →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your goal is to proactively identify older patients (65+) at elevated risk of developing new-onset atrial fibrillation within the next year, using standard 12-lead ECGs. This algorithm is best suited for clinicians focused on early risk stratification and preventative follow-up for AF in an at-risk geriatric population, even before symptoms manifest.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cardiologs Holter Platform	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	Cloud	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiologs Holter Platform

Cardiologs Holter Platform (Tool A) offers a cloud-based SaaS solution with 'anytime, anywhere access' and 'vendor-neutral compatibility,' suggesting a highly flexible and accessible user experience. It also emphasizes generating 'easy-to-read, automatically enriched reports' and reducing analysis time by 42%, directly enhancing usability for healthcare professionals.

Clinical Value

Tie

Both tools offer significant, yet distinct, clinical value. Tool A (Cardiologs) excels in efficiently and accurately detecting over 20 types of arrhythmias from Holter ECGs, streamlining current diagnostic workflows. Tool B (Tempus) provides a novel predictive capability, identifying patients at increased risk of developing AF within 12 months, enabling proactive intervention.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF (Tool B) explicitly highlights CMS reimbursement availability with specific CPT codes and a Medicare rate of $128.90, effective January 1, 2025. This transparency and clear reimbursement pathway offer a tangible financial value proposition for healthcare providers. Cardiologs Holter Platform (Tool A) only states 'pay per ECG' without specific pricing or reimbursement details.

Enterprise Readiness

Cardiologs Holter Platform

Cardiologs Holter Platform (Tool A) demonstrates strong enterprise readiness through its cloud-based SaaS deployment on ISO/IEC 27001 certified AWS servers, robust EMR integration (Philips IntelliBridge Enterprise), and vendor-neutral compatibility. While both are FDA cleared and HIPAA compliant, Tool A's explicit security certifications and broader integration capabilities provide a slight edge.

Innovation

Tempus ECG-AF

Tempus ECG-AF (Tool B) stands out for its innovative predictive capability, identifying patients at risk of developing new-onset Atrial Fibrillation within 12 months from a standard 12-lead ECG. This represents a forward-looking application of AI in preventive cardiology. Cardiologs Holter Platform (Tool A) focuses on optimizing existing Holter analysis workflows, which is valuable but less novel than predicting future disease.

Support & Docs

Tie

Both Philips (for Cardiologs) and Tempus AI are established companies in the healthcare technology sector, and their websites indicate the availability of technical support and documentation. However, the provided information and web searches do not offer sufficient comparative details regarding the depth, responsiveness, or specific features of their support and documentation to definitively declare one superior to the other.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cardiologs Holter Platform	Tempus ECG-AF
Name	Cardiologs Holter Platform	Tempus ECG-AF
Company	Philips France Commercial	Tempus AI, Inc.
ECG Type Analyzed	Holter ECG	12-lead ECG
Primary Detection/Outcome	Detects over 20 types of arrhythmias, reduces Holter analysis time.	Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Target Patient Population/Use Case	Streamline cardiac diagnostics for healthcare professionals.	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

Videos

Demos, reviews, and walkthroughs featuring Cardiologs Holter Platform and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application and target patient population for each tool?

The Cardiologs Holter Platform is designed for fast and accurate analysis of Holter ECGs to detect over 20 types of arrhythmias in both adult and pediatric populations. Tempus ECG-AF, conversely, analyzes 12-lead ECGs to identify patients aged 65 or older, without pre-existing AF or certain other conditions, who are at increased risk of developing atrial fibrillation/flutter within the next 12 months.

What type of ECG data does each platform analyze?

The Cardiologs Holter Platform analyzes continuous ambulatory ECGs from Holter devices, and is vendor-neutral, compatible with multiple Holter devices. Tempus ECG-AF analyzes resting 12-lead ECG recordings and is compatible with FDA-authorized 12-lead ECG machines from GE Medical Systems and Philips Medical Systems.

What specific AI capabilities does each tool offer?

The Cardiologs Holter Platform uses AI-powered deep learning technology to analyze ECG waveforms and detect over 20 types of arrhythmias, aiming to reduce analysis time by approximately 42%. Tempus ECG-AF employs an AI-based algorithm trained on over 1.5 million ECGs to identify subtle patterns indicative of a patient's increased risk of developing new-onset AF within 12 months.

Are there any limitations or specific considerations for interpreting results from each tool?

The Cardiologs Holter Platform's interpretation results are advisory and not intended as the sole means of diagnosis, requiring physician knowledge and other clinical information. Similarly, Tempus ECG-AF results should be interpreted in conjunction with other diagnostic information and clinical history, and it is not intended as a stand-alone diagnostic tool or for patients with pre-existing AF or certain other conditions.